United Therapeutics Corporation (UTHR) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($5.4 million) and the uptick to downtick ratio was 0.63. The transaction value on upticks was $9.13 million and on downticks, the transaction value was $14.53 million. The transaction value of block trades during downticks was $3.32 million. The money flow was negative ($3.32 million), indicating the traders were booking profit on the price strength. United Therapeutics Corporation (UTHR) rose $0.97 at $110.21, during intraday Thursday , a rise of 0.89% over the previous days close.
The stock has recorded a 20-day Moving Average of 4.04% and the 50-Day Moving Average is 0.13%. Shares have dropped -37.02% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $181.03 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $110.29 and the 200 Day Moving Average price is recorded at $119.64.
United Therapeutics Corporation (NASDAQ:UTHR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $110.58 and $109.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $110.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $110.21, notching a gain of 0.89% for the day. The total traded volume was 430,793 . The stock had closed at $109.24 on the previous day.
In an insider trading activity,The director officer (Chairman & CEO) of United Therapeutics Corp, Rothblatt Martine A sold 1,293 shares at $110.02 on July 7, 2016. The Insider selling transaction had a total value worth of $142,256. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.